Treatment of a subgroup of heavily pretreated MM patients with CH5126766, a dual RAF-MEK inhibitor, induced durable partial response in one patient and durable disease stabilization in another, both patients carrying KRAS mutations [171]. Here, MAP2K7 is linked to Miyoshi myopathy.